

OpSens focuses mainly on coronary artery stenosis measurement in interventional cardiology. OpSens offers an advanced optical-based pressure guidewire (OptoWire) that aims at improving the clinical outcomes of patients with coronary artery disease. OpSens is also involved in industrial activities.

Cornerstone for OpSens' Growth

Enhanced Financial Position

- \$28.75 M bought-deal financing - February 2021

Financial Performance

- Continued growth in revenues and margins


Business Growth

- Coronary artery stenosis products supported by key opinion leaders and medical publications
- 5-year supply contract - Abiomed
- New agreements with two major U.S. group purchasing organizations, including Vizient - one third of all U.S. cathlabs (approx. 700)
- Technology fosters business partnerships

Innovation

- New product - major opportunity for treatment of aortic valve stenosis (TAVR)
- Optimization of current products (performance & margin)

OPS Revenue



Shares outstanding **106 M**

Number of employees **180**

Legs for Growth and Value Creation

Based on Fidela,TM its second-generation fiber optic sensor, OpSens has designed the OptoWire, a guidewire to assess and guide the treatment of coronary artery stenosis. This guidewire has been used in the diagnosis and treatment of 100,000 patients worldwide.

OpSens now intends to capitalize on the expertise acquired in the development of its product for coronary artery stenosis to extend its activities to structural cardiology, with a new pressure guidewire to assist in the positioning of valves in the treatment of aortic valve stenosis (TAVR) - currently the fastest growing segment in cardiology.

OpSens' technology can be adapted to different applications, allowing the Company to enter business partnerships in various profitable markets.

Coronary Artery Stenosis Market: \$1 Billion in 2025¹

- Product : OptoWire
- Diagnosis and treatment of coronary blockages
- Treatment of 100,000 patients
- Medical publications
- Support from key opinion leaders
- Worldwide sales channels

Aortic Valve Stenosis Market: \$ 4 Billion in 2020²

- Product : Guidewire
- Transcatheter aortic valve replacement (TAVR)
- Fastest growing segment in structural cardiology

Business Partnerships Sensor can be used in several applications, markets

Medical



Industrial



1. Growth projected in Global FFR Market 2016-2020

2. Global TAVR/Implantation, Kenneth Research, 2018

**Coronary Artery Stenosis- Solid Business with Steady Growth
Market to reach \$1 billion by 2025¹**

OpSens responded to unmet needs with an improved offer.
OptoWire, an optical guidewire for the diagnosis and treatment of coronary artery stenosis.



WORKHORSE PERFORMANCE: Pressure guidewire design,
Excellent shape retention = control, torque, support for easy vessel access



ACCURACY: 2nd generation fiber optic sensor designed to provide lowest drift in the industry, consistent, repeatable measurements



CONNECTIVITY: Optical contact immune to procedural contaminants - Disconnect/reconnect with confidence to diagnose and deliver stents on the same guidewire.

One wire from start to finish saves time and money.

FAME 1² & 2, DEFER, COURAGE STUDIES
When the lesions of a patient are evaluated by physiological measurements (eg FFR) before a treatment is selected, rate of major cardiac events is considerably reduced.


1. Growth projected in Global FFR Market 2016-2020
2. Jan 15, 2009 NEJM 2009; 360:213-224
DOI: 10.1056/NEJMoa0807611

Structural Cardiology - The fastest growing segment in cardiology

OpSens has what it takes to quickly enter a market that will reach \$8 billion in 2025³

OpSens is working on the first pressure guidewire to confirm positioning of valves in the treatment of aortic stenosis. This strategic product will help optimize the positioning of valves in the treatment of aortic valve stenosis (TAVR) - currently the fastest growing segment in cardiology also called the TAVR procedure.

PARTNER 3 & EVOLUT studies support TAVR for all-comers population.



3. Global TAVR/Implantation, Kenneth Research

Opsens has what it takes to enter the market quickly.

Requirements	OpSens' Offer	FFR Requirements	TAVR Requirements
Sensor 2 nd generation Lowest-drift in the Industry	Accuracy in studies and clinical use	✓	✓
Guidewire Capabilities	One wire to Diagnose & Deliver	✓	✓
Sales Channels	Growing revenues Worldwide networks	✓	✓
Display Device	Several thousands of OptoMonitor in labs	✓	✓
Connectivity	Flawless connection	✓	✓

Industrial Segment

Opsens' versatile technologies can answer needs in key markets. There is a positive sentiment around our Fabry-Perot technology (single-point measurement) in leading areas. This growing interest stems from the fact that traditional technologies do not perform as expected under certain conditions, opening avenues for Opsens' fiber optic technology.

Opsens capitalizes on its easily adaptable technology and invests to offer applications to growing markets, like the monitoring of structures and various other applications in sectors such as aerospace, laboratories and semiconductors.

News: OpSens Solution awarded a contract from RI Research Instruments GmbH for absolute and differential fiber optic pressure sensors for ITER (International Experimental Thermonuclear Reactor).

Contacts

Louis Laflamme, CPA, CA - President & CEO
louis.laflamme@opsens.com

Robin Villeneuve, CPA, CA - CFO
robin.villeneuve@opsens.com

Marie-Claude Poitras - Communications
marie-claude.poitras@opsens.com

Opsens Inc.
750 Blvd du Parc-Technologique
Quebec, QC G1P 4S3
418.781.0333